Mereo BioPharma Files 8-K
Ticker: MREO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulation-fd
TL;DR
Mereo BioPharma filed an 8-K on Jan 13, 2025, for events on Jan 12. Details TBD.
AI Summary
Mereo BioPharma Group plc filed an 8-K on January 13, 2025, reporting events as of January 12, 2025. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Mereo BioPharma Group plc is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate high risk.
Key Players & Entities
- Mereo BioPharma Group plc (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Date of report
FAQ
What specific events are being reported under Regulation FD?
The provided excerpt does not specify the details of the Regulation FD disclosure.
What financial statements and exhibits are being filed?
The excerpt states that financial statements and exhibits are being filed, but does not list them.
What is the principal executive office address of Mereo BioPharma Group plc?
The principal executive office is located at 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom.
What is the Commission File Number for Mereo BioPharma Group plc?
The Commission File Number is 001-38452.
What is the Standard Industrial Classification for Mereo BioPharma Group plc?
The Standard Industrial Classification is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-13 06:32:39
Filing Documents
- mreo-20250112.htm (8-K) — 49KB
- mreo-ex99_1.htm (EX-99.1) — 39KB
- 0000950170-25-004523.txt ( ) — 256KB
- mreo-20250112.xsd (EX-101.SCH) — 57KB
- mreo-20250112_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 12, 2025, Mereo BioPharma Group plc (the "Company") issued a press release providing an update on its lead clinical programs. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release, dated January 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. MEREO BIOPHARMA GROUP PLC Date: January 13, 2025 By: /s/ Christine Fox Name: Christine Fox Title: Chief Financial Officer